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Abstract  
The discovery of Helicobacter pylori (H. pylori) by Warren and Marshall in 1982 was preceded by nearly a hundred year of inconspicuous 
publications in regard to spiral bacteria, achlorhydria, gastritis, gastric urease, and antimicrobial therapy for peptic ulcers. The infection has now 
been implicated in the etiopathogenesis of chronic gastritis, peptic ulcer disease (PUD), gastric carcinoma, and gastric mucosal associated lymphoid 
tissue (MALT) lymphoma. The understanding of the etiopathogenesis of dyspepsia and the approach to its management continues to evolve such 
that PUD and MALT lymphoma are now being considered as infectious diseases in which elimination of the causative agent cures the conditions. 
Various diagnostic tests with good diagnostic accuracies have been developed and effective multiple antimicrobial therapies are now available for 
the eradication of the infection. Despite the substantial progress made, there still exits a considerable gap to be filled. A significant number of 
information generated from studying the bacterial characteristics and host response to the infection has not yet been translated into clinical 
practice. A major challenge is the absence of a specific antibiotic monotherapy for effective treatment of the infection. 
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Introduction 
 
It has been abundantly demonstrated that H. pylori plays a major 
role in several upper gastrointestinal diseases which present as 
dyspepsia since its discovery in the early 1980s by Warren and 
Marshall [1,2]. Helicobacter pylori is usually found under the mucus 
layer in the gastric pits in close apposition to gastric epithelial cells 
where it causes chronic active gastritis [3]. It is a major etiological 
factor for PUD, gastric carcinoma, and gastric MALT lymphoma 
[1,4]. This discovery has generated significant interest in research 
on the organism with attendant continual evolution of the approach 
to investigation and treatment of patients with dyspepsia. Prior to 
the discovery of H. pylori the hyperacidity theory held sway in the 
pathogenesis of PUD. Various diagnostic tests with good diagnostic 
accuracies have been developed and effective multiple antimicrobial 
therapies are now available for the eradication of the infection [2,5]. 
Peptic ulcer disease and MALT lymphoma are now being considered 
as infectious diseases in which elimination of the causative agent 
cures the conditions because of the current level of understanding 
of the organism [3]. 
  
Despite the substantial progress made, there still exits a 
considerable gap to be filled. Some important information generated 
from studying the bacterial characteristics and host response have 
not yet been translated into clinical practice. A major challenge is 
the absence of a specific antibiotic monotherapy for effective 
treatment of the infection. This review appraises H. pylori in regard 
to the historical perspective, the current scientific understanding of 
the organism on its various aspects that are relevant to the clinician 





Relevant literatures on the subjects in texts books and scientific 
journals were reviewed. Extensive internet literature search for both 
original research and review articles in biomedical databases was 
made through Google scholar, PubMed, HINARI and Ovid. Keywords 
employed were “Helicobacter pylori”, “Dyspepsia”, “Peptic ulcer 
disease” “Gastric cancer”, “Epidemiology” and “Management”. The 
bibliographies of the articles on hand were used to find other 
references. An electronic reference manager (Mendeley) was used 
to store the articles. Of the 230 articles reviewed,82 were cited in 
the final draft of the article. 
Current status of knowledge 
 
Historical perspective (Historical timeline) 
 
The discovery of H. pylori, by Warren and Marshall, was preceded 
by nearly a hundred year of inconspicuous publications relating to 
spiral bacteria, achlorhydria, gastritis, gastric urease, and 
antimicrobial therapy for ulcers [6]. Investigation of gastric bacteria 
properly began in the latter half of the 19th century when 
microscope resolution had sufficiently advanced [7]. 
  
Bottcher and Letulle firstly hypothesized that bacteria caused ulcer 
disease in 1875, after they discovered bacteria in the floor and 
margins of gastric ulcers. In 1889 Walery Jaworski described spiral 
organisms (Vibrio rugula) in gastric washings. He suggested that 
these organisms might be implicated in causation of gastric disease. 
Similar spiral organisms were found in stomach of humans and 
other species by several scientists between then and the 20th 
century. For instance, in 1893 Bizzozero noted spirochetes in the 
gastric mucosa of dogs, which were named H. bizzozeroni. Kasai 
and Kobayashi in 1920 isolated spirochetes in cats and transmitted 
them to rabbits to produce ulcers [7]. 
  
Warren in 1979 identified Campylobacter pylori as the putative 
causative agent of human gastritis [7,8]. Culture of the organism 
(H. pylori) was elusive until 1982 when it was obtained by Barry 
Marshall [6]. Earlier attempts to culture the organism proved 
abortive because incubation was usually limited to 48 hours. 
Success at culture was incidental, as one of them spanned a holiday 
period and hence, lasted for 5 days, thereby yielding a growth. 
History was then made in April 1982 at the Royal Perth Hospital in 
Australia where H. pylori was cultured. Examination of the plate 
showed a pure growth of 1mm transparent colonies. Gram stains of 
the colonies showed slightly curved organisms and not spiral as in 
the smear of the specimen, which made Marshall to doubt whether 
it was the organism in question that was grown. Armstrong and 
Wee produced electron micrograph scans from the culture obtained, 
which showed that the bacterium was a spiral organism with five 
flagella. 
  
Further studies on the organism and its RNA sequence in ribosomes 
helped correct the earlier misconception that the organism belonged 
to the Campylobacter family (initially called Campylobacter 
pyloridis). At the 5th International Campylobacter workshop in 
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Mexico in February, 1989 the Campylobacter taxonomy committee 
agreed that H. pylori should no longer be included in 
the Campylobacter group. There was initial difficulty in 
nomenclature before Steward Goodwin who was head of the 
Microbiology Department at Royal Perth Hospital at that time 
reportedly suggested „Helicobacter‟, and this was published in 1989. 
  
The World Health Organization classified H. pylori as a class 1 
(definite) carcinogen implicated in the etiopathogenesis of gastric 
malignancies in 1994 [9]. Parsonnet et al. also describe an 
association between H. pylori and gastric lymphomas [10]. Tomb et 
al. completed the sequencing of the entire 1,667,867 base pairs of 
the H. pylori genome in 1997 [11]. And in 2005 Warren and 
Marshall were awarded the Nobel Prize in Physiology or Medicine for 
their work on H. pylori and PUD [12]. 
 
Epidemiology and transmission 
  
Helicobacter pylori infection occurs globally, but the prevalence 
differs among countries and population clusters within the same 
country [1]. The prevalence of the infection is associated with age, 
socioeconomic class, and country of origin [13]. Prevalence rates 
ranging from 20-50% are reported in the adult populations of the 
developed world but the prevalence is much more in the developing 
countries with prevalence as high as 90% in some countries [1,4]. 
Higher prevalence exists in regions of low socioeconomic and poor 
sanitary conditions, and in rural as contrasted to urban areas. The 
socioeconomic status of the family during childhood appears to be 
the major marker of infection [14]. There is an age-related increase 
in prevalence in the developed countries which is a reflection of 
birth cohort effect [14]. The general belief is that infection takes 
place mostly in childhood and the rate of acquisition has reduced 
with improved sanitary condition and probably antibiotic use among 
children in the developed world. Genetic susceptibility to infection 
has been demonstrated by studies that showed a higher 
concordance rate of the infection among monozygotic twins reared 
apart or together than in age-matched dizygotic twins [15]. 
  
H. pylori has been found in water; stomach of animals like cat and 
sheep; and milk of goat, sheep and cow [16]. Despite these, 
available evidence suggests that humans are the primary reservoir 
and that H. pylori in animals represents an anthroponosis 
[17]. Helicobacter pylori has been found in saliva and dental plaques 
of humans [18,19]. Some studies have suggested that dental 
plaques serve as reservoir for both person to person transmission of 
the organism and re-infection after successful eradication of 
organism [19]. The primary mode of transmission is person to 
person and clusters are found in families. This can be through oral-
oral, feco-oral, and gastro-oral (through gastric secretions, vomitus, 
and improperly disinfected endoscopes). The infection could also be 
transmitted from water [20]. 
  
Bacteriology and pathogenesis 
  
Helicobacter pylori is a microaerophilic slow–growing gram negative 
spiral organism. It is 0.5 to 8.0µm wide and has multiple 
ensheathed flagella at one end [21]. It has the capability of dual 
existence in bacillary and coccoid forms [22]. The bacillary form is 
motile while the coccoid form is non-motile. The genome of the 
organism codes for about 1,500 proteins [1]. Bacterial etiology of 
dyspepsia has been disputed in the past because of the knowledge 
that the stomach is unfavorable to bacterial growth due to its high 
acid content but H. pylori is able to overcome this by means of 
virulence factors which enhance colonization of the gastric 
epithelium and induction of tissue damage. 
  
The actual outcome of H. pylori infection (gastritis, PUD, gastric 
MALT lymphoma or gastric cancer) is determined by a complex 




These include factors that enhance mucosal colonization and factors 




Flagella: The possession of spiral shaped, unipolar, sheathed 
flagella [23] allows the organism to move rapidly from the lumen of 
the stomach, where the pH is low, through the mucus layer to an 
area where pH is near neutral to permit optimal growth. 
  
Urease: H. pylori has a great capacity for urease production, 
probably more than almost all other bacterial species. Urease 
hydrolyses urea to produce ammonia (NH3) and carbon dioxide 
(CO2). The presence of NH3reduces the acidity of the stomach; 
which may be necessary for providing a congenial environment 
for H. pylori. Ure1, a pH-gated channel helps to regulate the 
production of urea [1]. Possession of urease however, may not be 
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absolutely essential for colonization because urease negative H. 
pylori have been cultured from patients with duodenal ulcer. 
  
Adherence factors: H. pylori has tissue tropism for the gastric 
epithelium. It possesses fibrillar adhesins, located on its surface 
which binds closely to the carbohydrate receptors on the mucosal 
cell leading to the formation of an adherence pedestal [1]. The 
best-characterized of these adhesins is BabA, which is a 78-kD 
outer-membrane protein that binds to the fucosylated Lewis B blood 
group antigen. BabA is relevant in H. pylori associated disease and 
may influence disease severity, although the results of several 
studies are contradictory [1]. This property prevents the organism 
from being shed during cell and mucus turnover. 
  
Factors mediating tissue injury 
  
Lipopolysaccharides (LPS): They are glycolipids found in the cell 
envelope of gram negative bacteria of which H. pylori is one. 
Lipopolysaccharides are endotoxins which stimulate the release of 
cytokines through their lipid A component. They also interfere with 
gastric epithelial cell–laminin interaction, which may lead to loss of 
mucosal integrity; inhibit mucin synthesis, and stimulate pepsinogen 
secretion [24]. 
  
Leukocyte recruitment and activating factors: These are 
soluble surface proteins with chemotactic properties produced by 
the organism. They help to recruit monocytes and neutrophils to the 
lamina propria and to activate these inflammatory cells. These 
include H. pylori neutrophil-activating protein, expressed by the 
napA gene, and the immunologically active porins [25]. 
  
Vacuolating Cytotoxin (VacA): It is a protein that induces 
vacuole formation in eukaryotic cells. It is encoded by 
the vacA gene [1]. All strains of H. pylori possess the vacA gene, 
but only about 50% express the mature protein. Antibodies to VacA 
can be used to detect VacA-producing H. pylori strains. VacA is an 
exotoxin, which inserts itself into the epithelial cell membrane to 
form a hexameric anion-selective, voltage-dependent channel 
through which bicarbonate and organic anions can be released [26]. 
It also acts on the host mitochondrial membrane to induce 
apoptosis leading to release of cytochrome c from the 
intermembrane space [27]. 
  
Cytotoxin-Associated Antigen (CagA): It is a highly antigenic 
protein encoded by the cagA gene that is part of the cag 
pathogenicity island (Cag PaI). The presence of Cag PaI is 
associated with a more prominent tissue inflammatory response 
than is seen with strains lacking it. This increase in inflammation is 
associated with an increased risk of developing a symptomatic 
outcome of the infection, especially PUD and gastric 
adenocarcinoma [28]. Antibodies to CagA can be used to detect 
CagA-producing H. pylori strains. The cag PaI encodes a type IV 
secretory apparatus that injects CagA into mammalian cells [29] 
where it triggers cytokine production. Cag PaI-positive H. pylori also 
induces apoptosis via the mitochondrial pathway [27]. Apoptosis of 
epithelial cells compromises epithelial barrier which protect the 
epithelium against luminal acid and pepsin. 
  
Outer Membrane Inflammatory Protein(OipA): It is possessed 
by most strains with CagA. It acts synergistically with CagA to 
produce a more intense inflammatory response than would have 
otherwise occurred in either [30]. 
  
Heat shock proteins: These are highly antigenic heat shock 
proteins known as HspA and HspB. Their role in the pathogenesis of 
the infection is still not fully known. It has been observed that, even 
in the absence of VacA and CagA, H. pylori can sensitize human 
gastric epithelial cells and enhance susceptibility to tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis 
[31]. The infection chronicity is sustained through suppression of H. 
pylori specific memory CD4+ T-cell responses by antigen specific 




H. pylori does not invade the gastric mucosa but its attachment to 
the surface mucosal epithelial cells sets off a remarkable cellular and 
humorous host immune responses. It provokes a chronic 
inflammatory response involving recruitment of neutrophils, 
followed by T and B lymphocytes, plasma cells and macrophages, 
which altogether cause gastric epithelial damage by their activities 
[33]. Human antibody response to H. pylori lipopolysaccharide (LPS) 
is majorly IgG antibodies directed against a highly immunogenic 
antigenic-epitope in the polysaccharide chain of H. pylori LPS. The 
dominant subclass is IgG2. There are also IgA and IgM responses, 
but they are less specific. H. pylori infection also enhances the 
release of interleukin-1β (IL1β), interleukin-2 (IL-2), interleukin-6 
(IL-6), interleukin-8 (IL-8) and tumor necrosis factor (TNF) [34]. 
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As Part of the host immune response to invading microorganisms T 
cell subgroups are produced which assist in protecting the mucosa 
and distinguishing pathogenic bacteria from commensals [35]. 
Immature T helper (Th) 0 cells expressing CD4 have the ability to 
differentiate into two functional subtypes: Th 1 cells which are 
induced mostly in response to intracellular antigen and secrete 
interleukin-2 (IL-2) and interferon-γ (IF-γ); Th 2 cells which are 
induced in response to extracellular pathogens and secrete 
interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-10 (IL-10). 
  
From the foregoing, it is expected that H. pylori would provoke 
inflammatory response via Th 2 cells, being an extracellular antigen. 
The contrary is however true, as Th 1 response has been observed 
to be predominant [36].This distorted response results in an 
imbalance production of the pro- and anti-inflammatory cytokines 
regulated by the Th cells and may subsequently result in tissue 
damage similar to what is seen in autoimmune diseases [37]. Class 
II MHC molecules on the host cell act as receptors for H. pylori to 
this effect [36,37]. 
  
H. pylori-stimulated gastric epithelial cells produce monocyte 
chemo-attractant protein I (MCP-I) which cause cyclooxygenase 2 
(cox-2) induction and activation of T-cells [38]. Additional 
mechanisms by which H. pylori may cause epithelial cell injury 
include: activated neutrophil-mediated production of reactive 
oxygen and nitrogen spp., enhanced epithelial cell turnover and 
apoptosis due to chronic inflammation which may be as a result of 
the combined effect of direct Fas-mediated contacts between 
epithelial and Th1 cells and interferon-γ [1]. 
  
Pro-inflammatory polymorphisms of the interleukin-1β gene favor 
the development of stomach body predominant gastritis that is 
associated with hypochlorhydria, gastric atrophy, and gastric 
adenocarcinoma. Absence of these pro-inflammatory polymorphisms 
leads to development of H. pylori associated antral predominant 
gastritis which is associated with a normal to high level of acid 
secretion [1]. 
  
Disease spectrum It has been demonstrated that H. pylori is 
involved in the pathogenesis of several diseases [1,39]. These 
include: 
  
Gastritis: This could occur in form of either acute or chronic 
gastritis. The inflammatory mechanisms described above are some 
of the ways by which H. pylori causes gastritis. Acute infection is 
typically manifested as a transient mild illness characterized by 
epigastric pain, nausea, histological finding of neutrophilic gastritis 
and a transient hypochlorhydria [4].It is not known how often acute 
infection clears spontaneously. However, studies in children suggest 
that spontaneous loss of infection may be common [15]. Acute H. 
pylori infection is diagnosed by the presence of a positive UBT and 
negative IgG anti–H. pylori antibodies [4]. Chronic gastritis often 
presents in form of chronic active, non-atrophic superficial antral 
gastritis, with a picture of focal epithelial cell damage [4]. This is 
usually asymptomatic, although it may be associated with PUD. 
Chronic atrophic gastritis resulting from progression of the non-
atrophic chronic gastritis may also occur in a smaller percentage of 
patients with gastritis. 
  
Peptic ulcer disease: An individual infected with H. pylori has an 
estimated lifetime risk of about 10-20% for the development of 
PUD. This is at least 3-4 folds higher than in non-infected 
subjects. H. pylori infection can be diagnosed in 90-100% of 
duodenal ulcer (DU) patients and in 60-100% of gastric ulcer (GU) 
patients [40]. The gastritis induced by H. pylori can progress to 
ulceration of the mucosa. Apoptosis of epithelial cells and 
subsequent compromise in the mucosal protective barrier exposes 
gastric mucosa to the direct assault of luminal acid and pepsin. 
Occlusion of mucosal end-arteries due to impaired fibrinolytic 
activity may contribute to the focal nature of PUD [41]. NSAID 
ingestion also increases the chances of developing GU. 
  
Patients with DU have been known, before the discovery of H pylori, 
tosecrete about twice as much acid as controls because they have 
twice as many parietal cells [42]. Acid hypersecretion in DU is 
virtually always due to H. pylori infection because secretion returns 
to normal after the infection is eradicated. The predominantly antral 
gastritis in DU diminishes the number of somatostatin-producing 
cells in the antrum. This leads to a reduction in production of 
somatostatin, reduced somatostatin-mediated inhibition of gastrin 
release from the G cells, and eventual development of 
hypergastrinemia [40].The increased acid secretion may, on its own, 
increase the risk of duodenal ulceration or may induce gastric 
metaplasia in the duodenum, which becomes colonized by H. pylori, 
then inflamed (duodenitis), and finally ulcerated [42]. Successful 
eradication of H. pylori leads to PUD healing and less frequent 
recurrence of the ulcer [43]. 
  
Gastric adenocarcinoma: H. pylori has been implicated as the 
strongest risk factor in the pathogenesis of gastric adenocarcinoma, 
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especially the distal type [1,44] and has thus, been classified as a 
class I (or definite) carcinogen by the WHO [9]. The pathogenesis of 
gastric cancer includes a sequence of events that begins with H. 
pylori-induced chronic superficial gastritis, progressing towards 
atrophic gastritis, intestinal metaplasia, dysplasia and eventually 
gastric cancer. This sequence takes decades to complete [9,44]. 
Several aspects of the inflammatory milieu that have been 
implicated as carcinogens include: increased oxidative stress and 
the formation of oxygen-free radicals leading to DNA damage, 
increased pro-inflammatory cytokine production such as IL-1β and 
TNF which stimulate greater cell turnover and reduced apoptosis, 
and potential for faulty or incomplete DNA repair [44]. 
  
Bacterial virulence has been shown to be an important factor in 
carcinogenesis. For instance, patients infected with CagA-positive 
strains have been shown to have a higher risk of developing gastric 
carcinoma than those infected with CagA-negative H. pylori strains 
[9,44]. 
  
H. pylori-infected cells also express some factors similar to those 
commonly implicated in carcinogenesis e.g. matrix 
metalloproteinase-7 (MMP-7) which has been found to be up-
regulated in colorectal cancer [45]. MMP-7 is important in the 
normal and pathological remodelling of epithelial-matrix interactions 
and is up-regulated in gastric cancer too. It plays an important role 
in promoting tissue invasion and metastasis of cancer cells. This up-
regulation is also dependent on the cag-PaI [45]. 
  
Although H. pylori is now thought to account for 80% or more of 
gastric cancers, it is noteworthy that only 3% of infected patients 
progress to gastric cancer [9]. This suggests that H. pylori infection 
only on its own is generally not sufficient to cause gastric carcinoma 
[46]. A combination of bacterial factors, environmental insults, the 
host immune response and other genetic factors is responsible. 
  
MALT lymphoma: The molecular pathogenesis of MALT lymphoma 
is incompletely understood but seems to also involve strain-
specific H. pylori factors, as well as host genetic factors, such as 
polymorphisms in the promoters of inflammatory cytokines such as 
IL-1B and TNF. It is believed that H. pylori infection leads to the 
formation of H. pylori-reactive T cells, which then cause polyclonal 
B-cell proliferations [47]. In time, a monoclonal B-cell tumour 
emerges in the proliferating B cells, probably as a result of 
accumulation of mutations in growth-regulatory genes. Some 
studies have implicated CagA in the development MALT lymphoma 
via impairment of p53-dependent apoptosis [48]. In keeping with 
this, eradication of H. pylori "cures" the lymphoma by removing 
antigenic stimulus for T cells [3]. 
  
Functional dyspepsia: The prevalence of H. pylori is generally 
high in patients with dyspepsia irrespective of the subgroup. The 
implication of H. pylori in the pathogenesis of ulcer dyspepsia is well 
established but there are dissenting views on the role it plays in the 
pathogenesis of functional dyspepsia. While some studies showed 
association between H. pylori infection and the clinical diagnosis of 
functional dyspepsia [49], others did not show any association [50]. 
  
Extra-gastroduodenal diseases: H. pylori has also been 
suggested to be causally related to several extra-gastroduodenal 
diseases [51]. These associations are generally weak because they 
were not obtained from randomized controlled studies [52]. A list of 




In view of the importance of H. pylori in the etiopathogenesis of 
major gastrointestinal and extra-gastrointestinal diseases, it is 
pertinent to look into cost-effective and reliable diagnostic tests for 
early detection and therapy. Helicobater pylori diagnostic tests can 
be broadly classified into invasive and non-invasive tests [2,5]. 
Invasive tests require endoscopic gastro-duodenal biopsy samples 
while the non-invasive tests do not [2,5]. 
  
Despite the good sensitivity and specificity of most of the commonly 
used tests, determination of gold standard has been difficult 
because none of them is perfect. A combination of at least two tests 
is commonly used as gold standard, though some researchers now 
use UBT as their gold standard [53]. It is not uncommon to use at 





Histology: Biopsies are obtained from the gastric antrum and 
corpus [55]. Multiple levels of each biopsy are routinely stained with 
haematoxylin and eosin (H&E) and with a special stain such as 
Warthin-Starry silver, Giemsa, or Cresyl-fast violet. The standard 
H&E stain is used to determine histological chronic or chronic active 
inflammation (gastritis) but could also demonstrate H. pylori if a 
large number of the organism is present. Atrophy and intestinal 
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metaplasia can also be assessed. Small numbers of bacteria are 
better detected by the special stains. An important advantage of 
histology is that in addition to the historical record provided, 
sections from biopsies (or even additional sections) can be 
examined in the future [54]. The drawbacks of the test include high 
observer-dependency, relatively long waiting time for result, 
requirement of specialized skills for performance and relatively high 
cost. 
  
Rapid urease test (RUT): The urease enzyme which is produced 
by H. pylori is utilized in performing this test. Gastric biopsy is 
placed in a medium that contains urea and a pH indicator. The 
urease breaks down the urea to produce ammonia that increases 
the pH of the medium which leads to a color change. The specificity 
and sensitivity of the test are greater than 90%, but false-positive 
results do occur [4]. It can be performed and read within 1 to 24 
hour depending on the make. Its comparative advantage to 
histology lies in its rapidity, simplicity and inexpensiveness; but it 
cannot be used to evaluate gastritis. 
  
Culture: This is done under stringent conditions. Endoscopy biopsy 
must be transported to the laboratory at 4°C within 24 hrs. or at -
70°C for a longer period. Fresh selective and non-selective media 
are needed to culture the organism. After introduction of the 
specimen into the culture medium, the plates are inspected for 
about 10 days. Due to the focal nature of inflammatory lesions 
produced by H. pylori, multiple biopsies are usually taken from the 
gastric antrum and corpus to increase the yield of the test. The 
specificity of the test is 100% while the sensitivity is slightly less 
[56]. A major advantage of the test is that, pure growth of the 
organism can be obtained for proper identification and detailed 
studies e.g. antibiotics sensitivity when there is failure of the second 
line drugs, strain typing, genetic studies etc. The disadvantages of 
the test include longer duration for result availability, high cost and 
the stringent condition needed for transportation to the laboratory. 
  
Polymerase chain reaction (PCR): This is a molecular technique 
which amplifies fragment of a gene specific for the H. 
pylori e.g. vacA and cagA gene sequences, 16SrNA, 23SrRNA, and 
ureC are targeted [56]. The biopsy is lysed to liberate the DNA. 
Specifically designed primers and polymerase enzyme are used to 
amplify gene. Amplification is done in 30-40 cycles at different 
temperatures with each cycle. This allows for denaturation, 
annealing and elongation. The amplified products are thereafter 
identified by electrophoresis. 
  
As a result of the development of string-capsule test device, gastric 
sample for PCR can now be obtained without having to biopsy the 
stomach [56]. PCR has a sensitivity and specificity that are well 
above 90%. It can be used to analyze bacterial genotypes, study 
pattern of antibiotic resistance and H. pylori transmission within 
families and the community. The main disadvantages are that it is 
expensive, and the procedure requires technical expertise to 
perform. 
  
DNA-Enzyme immunoassay: This is a form of PCR where the 
PCR amplicons are detected by calorimetric method. It is ELISA-
based and involves the use of coated microwells. This method is 
more rapid than the standard PCR and result can be obtained within 
a few hours [57]. 
  
Fluorescent in situ hybridization (FISH): This is another 
molecular test for diagnosing H. pylori that is particularly useful in 




Serology: chronic H. pylori infection elicits a circulating antibody 
response that can be quantitatively measured by serological assay 
technique like enzyme-linked immunosorbent assay (ELISA) [59]. 
Though tests for IgG, IgA and IgM antibodies can be done, only IgG 
antibody test is reliable. It involves the use of serum or plasma, and 
lately tests on whole blood (in office test) [57]. Microwells coated 
with H. pylori antigen are exposed to H. pylori antibody (in serum, 
plasma or whole blood) in the presence of an indicator. The color 
change resulting from the antigen-antibody reaction is read visually 
or with the use of a spectrophotometer. Other serological methods 
that can be used include immunoblot, flow microsphere 
immunofluorescence and chromatographic tests. 
  
Because of its easy availability, affordability, and simplicity, it is 
commonly used in prevalence studies of H. pylori. Its major 
drawback is its poor discriminatory power between current infection 
and previous exposure, since it may still be positive several months 
after H. pylori eradication. It is therefore generally not useful in 
confirming cure after antimicrobial therapy but it is useful for the 
initial diagnosis of H. pylori infection and epidemiological surveys 
[59]. 
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Urea breath test (UBT): This is an indirect method of detecting 
the presence of H. pylori in the stomach premised on the ability 
of H. pylori to produce the urease enzyme. Urea labeled with 
either 13C or 14C is ingested by the patient [60]. If urease is present 
in the stomach as a result of H. pylori infection, labeled CO2will be 
split off and absorbed into the circulation, where its presence can be 
determined by analysis of expired breath by means of a 
spectrometer. The result is expressed in delta/mil. 13C UBT is 
preferred to 14C UBT especially in children and pregnant women 
because it is stable and non-radioactive [61]. 
  
UBT is now being considered as the gold standard by some 
researchers [61]. It is the non-invasive test with the highest 
sensitivity and specificity (>95%) and is the preferred means of 
evaluating the success of antimicrobial therapy in clinical practice. It 
is not as expensive as endoscopy. Portable and cheaper 
spectrometers are now available thereby eliminating the need to 
send collected air samples to a central spectrometer. There is the 
possibility of false positive results when there is bacterial 
overgrowth of urease-producing organisms. Recent use of 
antibiotics, bismuth preparations or acid suppression therapy, due 
to their effect on the colony size of H. pylori, can produce false 
negative results. 
  
Stool antigen test (SAT): The test is based on the detection of H. 
pylori antigen in the stool. Helicobacter pylori adhering to gastric 
epithelium in infected persons appear in their stool as a 
consequence of the normal shedding of the epithelium. This means 
that the test is a direct test of active infection which gives it an 
advantage over serology. It is an enzyme immunoassay test which 
is available in both polyclonal and monoclonal forms. The 
monoclonal immunoassay is newer and more sensitive and specific 
than the polyclonal assay [58] and may be considered as an 
alternative to UBT in the initial diagnosis of patients with dyspepsia 
who do not require immediate endoscopy [62]. SAT is simple and 
relatively cheap. It can be carried out in most routine laboratories. 
It is slightly less reliable when used soon after the end of H. 
pylori eradication therapy. It is now generally recommended to wait 
for about 12 weeks to reliably confirm eradication [58]. Its 
diagnostic accuracy is impaired by PPIs and gastrointestinal 
bleeding [63]. A major drawback is related to the inconvenience of 
stool handling. Additional non-invasive tests that are yet to be 
recommended for routine clinical diagnosis of H. pylori include stool 
PCR, Urine antibody test and Saliva antibody test [9,64]. The 
accuracy of some of the commonly used Helicobacter 




It is appropriate for all patients with dyspepsia who are positive 
for H. pylori to undergo H. pylori eradication therapy because of the 
strong association between H. pylori and the diseases manifesting 
clinically as dyspepsia [1–3]. This is particularly important 
because H. pylori eradication has been associated with significant 
reduction in the rate of recurrence of PUD and cure of MALT 
lymphoma. The specific recommendations for treatment include 
patients with PUD and MALT lymphoma; patients with atrophic 
gastritis; first degree relatives of patients with gastric cancer; 
patients with unexplained iron deficiency anemia; and patients with 
chronic idiopathic thrombocytopenic purpura [2,5]. 
  
The fact that no single agent is sufficient in eradicating the H. 
pylori is a major challenge [1,2,4,5]. Combinations of antibiotics 
together with non-antibiotic adjunctive agents are required for 
eradication of the organism. Drugs are given in combinations of 3 
(triple) or 4 (quadruple). Each regimen consists of at least 2 
antibiotics. Antibiotics that are traditionally used include amoxicillin, 
nitroimidazole (metronidazole or tinidazole), clarithromycin, 
tetracycline and bismuth. Adjunctive agents include Histamine-2 
receptor blockers (H2RB), proton pump inhibitors (PPI), and 
ranitidine-bismuth citrate (RBC). 
  
Triple therapy consists of two antibiotics and one adjunctive agent 
while quadruple therapy is made up of two antibiotics and two 
adjunctive agents. The use of dual therapy is discouraged because 
of wide spread antibiotic resistance. Regional antibiotic sensitivity 
pattern needs to be properly considered in the choice of antibiotics. 
The Maastricht III -2007 consensus report and the American College 
of Gastroenterology Association (ACG) suggested two lines of 
therapy [2,5]: first-line therapy: this can be a combination of a 
PPI with amoxicillin and clarithromycin; a PPI with amoxicillin and 
metronidazole, or a bismuth containing quadruple 
therapy; Second-line therapy: a quadruple therapy is often used 
after failure of first line therapy. Examples include a combination of 
a PPI with bismuth, metronidazole and tetracycline or a combination 
of ranitidine with bismuth, metronidazole and tetracycline. If 
bismuth is not available, a PPI-based triple therapy could be used. 
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Because failure rate is above 20% in most commonly used first-line 
therapies [65], there is often the need for a second line therapy. 
The choice of a second-line treatment is contingent upon the initial 
treatment. Most authorities agree that culture is not required after a 
first line eradication failure [2,66]. If a metronidazole-based 
treatment was used a clarithromycin-based regimen (or at least a 
metronidazole-free regimen) should be used thereafter, and vice 
versa [67]. This recommendation is grounded on the observation 
that acquired bacterial resistance to metronidazole or clarithromycin 
is often a result of previous treatment failure [68]. 
  
Another challenge in the treatment of H. pylori infection is the 
determination of the optimal duration of therapy. While there is 
controversy as to whether 7, 10, or 14 days is optimal [69,70]; it 
has been generally observed that longer [71] durations provide 
better results than a 7 day duration [72]. The current European and 
United States‟ recommendations support a 14 day duration therapy 
[2,5]. Notwithstanding the foregoing, available evidence suggests 
that a 7-day treatment duration is sufficient when quadruple 




An ideal H. pylori therapy should have a short duration and ought to 
lead to an eradication rate of the organism greater than 90%, as 
was the case initially when the triple-therapy regimens were 
approved [74]. A decreasing efficacy of common regimens has been 
observed with failure rates now surpassing 20% [5,75,76]. This 
development most likely result from increased bacterial resistance to 
some of the antibiotics in the regimens, especially clarithromycin 
that is often used [76]. The regimen comprises of a PPI and 
amoxicillin for 5 days followed by a PPI, clarithromycin, and a 5-
nitroimidazole (tinidazole or metronidazole) for another 5 days [74]. 
Sequential therapy originated from Italy and the original therapy 
utilized tinidazole [74,76]. Several studies from Italy and other parts 
of the world have reported eradication rates exceeding 90% which 
is superior to the clarithromycin-based triple therapy [5,74,76]. The 
tolerability is good in children, adults and the elderly [5]. The basis 
for this more complex therapy is the belief that amoxicillin could 
weaken bacterial cell walls in the initial phase of treatment, thereby 
preventing the development of drug efflux channels that inhibit 
drugs like clarithromycin from binding to ribosomes [74]. This 
therapy has a potential to become the standard first-line treatment 
for H. pylori infection because of this observed advantage. 
  
Third line and ‘Rescue’ therapies 
  
Treatment of patients who have already undergone first- and 
second-line therapies is a challenge because of the risk of 
development of double antibiotic resistance [77]. Though, various 
therapeutic protocols have been tested by different groups, a 
standard third-line therapy is currently lacking [2,78]. Endoscopic 
biopsy culture and antibiotic sensitivity testing is the most suitable 
option for patients with two eradication therapy failures [2,78]. The 
third-line therapy should avoid metronidazole and clarithromycin 
and other antibiotics that are likely to have contributed to 
development of the resistance. 
  
Other classes of antibiotics that have emerged in the treatment 
of H. pylori, especially for „rescue‟ therapies include: 
fluoroquinolones like levofloxacin (gatifloxacin and moxifloxacin); 
rifabutin (rifamycin); and furazolidone (a nitrofuran) [2,4,78,79]. 
They can be used to replace clarithromycin and metronidazole in 
rescue therapies and in first or second line regimens [2,78-80]. 
They are particularly important because the use of quadruple 
therapy as the optimal second-line therapy is plagued with problems 
of a relatively high incidence of adverse effects and regimen 
complexity [79]. These lead to poor compliance, failure of 






Substantial progress has been made in the understanding of the 
pathogenicity and treatment of H. pylori but there still exits a 
considerable gap to be filled. Information generated from studying 
the virulence factors of H. pylori are yet to be translated to clinical 
practice. Associations between bacterial characteristics and disease 
risks have not been defined sufficiently to guide the clinician in 
treatment decisions [1]. A major challenge exists in developing 
specific antibiotic monotherapy for effective treatment of the 
infection. Since the H. pylorigenome has now been sequenced, this 
provides an opportunity both to identify specific targets for drug 
therapy, and to facilitate the identification and production of 
antigens that may be helpful in manufacturing vaccines [81]. 
Encouraging results from animal models have been obtained in the 
areas of both therapeutic and prophylactic vaccination; however, 
translation to human vaccine remains difficult probably because the 
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immunology of the human stomach is still poorly understood [82]. 
All these developments and more will be necessary to adequately 
treat and prevent H. pylori infection in the future, especially in 
regions of the world with high prevalence. 
 
What is known about this topic 
 H. pylori plays a major role in the pathogenesis of several 
upper gastrointestinal diseases that present as dyspepsia; 
 Reasonably sensitive and specific tests are available for 
diagnosing H. pylori; 
 Combination therapy for H. pylori eradication are 
available. 
 
What this study adds 
 The review is a summary of a myriad of materials already 
written on the topic presented in a concise and easy to 
read manner; 
 The sections on historical perspective and future direction 
on the topic were written to help stimulate the interest of 
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Table 1: Non-gastrointestinal tract diseases possibly associated 
with Helicobacter pylori Infection 





Vomiting of pregnancy 
Immune thrombocytopenic purpura 
Hyperammonemia 
Sudden infant death syndrome 
Growth retardation 





Table 2: Accuracy of diagnostic methods for Helicobacter pylori in % 
Method  Sens. Spec. PPV NPV 
Warthin-Starry silver stain+ 93 99 99 89 
Rapid Urease Test+ 90 100 100 84 
Serum IgG antibody 91 97 95 85 
Urea Breath Test 90 96 98 84 
From Cutler AF, Havstad S, Ma CK, et al: Accuracy of invasive and noninvasive 
tests to diagnose Helicobacter pylori infection. Gastroenterology. 1995; 
109(1):136-41.IgG = Immunoglobulin G, NPV = Negative Predictive Value, PPV 
= Positive Predictive Value; Sens. = Sensitivity, Spec. = Specificity. 
+In a gastric mucosal biopsy specimen 
  
 
